Market capitalization | HKD154.80b |
Enterprise Value | HKD147.55b |
P/E (TTM) P/E ratio | 15.86 |
EV/FCF (TTM) EV/FCF | 18.46 |
EV/Sales (TTM) EV/Sales | 3.54 |
P/S ratio (TTM) P/S ratio | 3.71 |
P/B ratio (TTM) P/B ratio | 2.56 |
Dividend yield | 2.02% |
Last dividend (FY23) | HKD1.09 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
19 Analysts have issued a WuXi AppTec forecast:
19 Analysts have issued a WuXi AppTec forecast:
Sep '24 |
+/-
%
|
||
Revenue | 41,736 41,736 |
7%
7%
|
|
Gross Profit | 18,905 18,905 |
6%
6%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | 10,967 10,967 |
8%
8%
|
Net Profit | 9,914 9,914 |
6%
6%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.
Head office | China |
CEO | Min Chen |
Employees | 41,116 |
Founded | 2000 |
Website | www.wuxiapptec.com.cn |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.